Research ArticleArticle
INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Ulf G. Eriksson
Hassan Dorani
Johan Karlsson
Holger Fritsch
Kurt-Jürgen Hoffmann
Lis Olsson
Troy C. Sarich
Ulrika Wall
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
Drug Metabolism and Disposition May 1, 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Research ArticleArticle
INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION
Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer
Drug Metabolism and Disposition May 1, 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement